Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer
- 1 June 2024
- journal article
- review article
- Published by Wiley in Cytopathology
- Vol. 35 (6) , 664-670
Abstract
The transformative role of artificial intelligence (AI) and multiomics could enhance the diagnostic and prognostic capabilities of liquid biopsy (LB) for lung cancer (LC). Despite advances, the transition from tissue biopsies to more sophisticated, non‐invasive methods like LB has been impeded by challenges such as the heterogeneity of biomarkers and the low concentration of tumour‐related analytes. The advent of multiomics – enabled by deep learning algorithms – offers a solution by allowing the simultaneous analysis of various analytes across multiple biological fluids, presenting a paradigm shift in cancer diagnostics. Through multi‐marker, multi‐analyte and multi‐source approaches, this review showcases how AI and multiomics are identifying clinically valuable biomarker combinations that correlate with patients' health statuses. However, the path towards clinical implementation is fraught with challenges, including study reproducibility and lack of methodological standardization, thus necessitating urgent solutions to solve these common issues.Keywords
This publication has 50 references indexed in Scilit:
- A review on trends in development and translation of omics signatures in cancerComputational and Structural Biotechnology Journal, 2024
- Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visibleCritical Reviews in Oncology/Hematology, 2022
- Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non‐small‐cell lung cancer treated with pembrolizumabMolecular Oncology, 2021
- Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021Critical Reviews in Oncology/Hematology, 2021
- Liquid biopsy approaches for pleural effusion in lung cancer patientsMolecular Biology Reports, 2020
- Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisionsMolecular Oncology, 2019
- Single tube liquid biopsy for advanced non‐small cell lung cancerInternational Journal of Cancer, 2018
- The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease MonitoringCurrent Oncology Reports, 2018
- RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer DiagnosticsCancer Cell, 2015
- Epidermal growth factor receptor mutation status in cell‐free DNA supernatant of bronchial washings and brushingsCancer Cytopathology, 2015